Depends on Current product growth and new indications plus what is in the pipeline and what other combinations drugs that Abbv has in the pipeline that my work with the new acquisitions products and pipeline. You may be right and you may be wrong but way too early to make statements like this.
That is why we elect board of directories. There is no time to wait around for stockholders to make up their minds and cast votes. Besides you can not show your hand when making deals.
As a stockholder, I am happy with $90 per share especially having Pfizer backing the deal. The only ones that will make out on all the law suits floating around are the ambulance chasing lawyers.
Humira, is taken for life and if a patient is doing ok on Humira a Doctor will think twice before prescribing a similar product. Also there are many other patents filed on humira just for the manufacturing and processing of the product. Also, Abbvie has been working on the next generation of this product.
Call Abbott Investor Relations up and see if this direction is really coming from Abbott Laboratories. Sounds to me that it could very well be your brokerage company not wanting to deal in lots smaller than 100 shares. I ran into this situation several years ago with a broker (Not with Abbott shares but with some other stocks) giving me the same pitch and I immediately transferred everything in the account to my other broker.
Where did you get the info that merger will be completed in Dec? The only thing that I have read is some are estimating that the merger could be completed as soon as the end of the second quarter baring any problems with the FTC and any foreign intervention.
If you owned the stock at $70 why didn't you sell? If you bought at $70 you only have yourself to blame. If you can not stand the heat get out of the market.
Abbvie and Gilead will do just fine long term. It will be at least July before all the pricing impact shakes out and we see real activity on scripts plus 2 quarters of income reporting. Until then both stocks are going to be bouncing around. Also more pipeline info will be available.
Investing is like the weather. Always changing and always a risk. Planning and staying informed is always important.
There is a lot of pricing pressure coming from all angles not just between companies but from payers and governments. The foreign markets will probably even be tougher, not to mention more companies entering into the market place. I too was not comfortable with the HEPC comments from management. I think they are probably conservative with what they have in their plans for Viekira Pak in 2015 since no dollar amount was mentioned only the year end run rate of $3Billion. Is the Japanese clinical product a one or two pill combo?. It looks like they have a next generation Hep C product in Phase IIB trials that if successful will be moving into Phase III in 2015.
Only statement that I heard is Abbvie would continue to buy back shares of the previously announced buy back plan. Did not hear any thing that would indicate an additional buy back plan.
You need to pay more attention to the conference call. There is no comment stating that they will have $3 Billion in Viekira Pak sales in 2015. The sales figure was never released and most companies do not release individual sales figures in guidance. The $3 Billion figure is the estimated run rate for December 2015 sales which would carry over into 2016. This was clarified several times during the conference call.